Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

IMproved Plasminogen Activator based on Cerium oxide nanoparticles for Thrombolysis in ischemic Stroke

Obiettivo

Ischemic stroke is the second cause of death worldwide. Recombinant tissue plasminogen activator (rtPA) is the only approved therapeutic agent. However, stroke patients often suffer from hemorrhages caused by oxidative stress, leading to high immobility rates. The project conducted at Université Paris Cité is at the cross-section of material science and nanomedicine. It aims to develop a nanomedicine for clot targeting, dissolution, and antioxidant therapy to treat ischemic stroke against oxidative stress. Combining the robust antioxidant activity of the cerium oxide nanoparticles (CeNPs) with the clinical-proven rtPA as a delivery vector, the novel nanomedicine will find its potential application for the care of stroke patients and beyond. CeNPs will be optimized to achieve the maximum antioxidant activity. It will be assembled with polymers and rtPA to preserve circulation time and delivery efficiency. The nanoassembly will be evaluated against oxidative stress and clot dissolution efficiency. The project combines the Researcher's experiences in developing advanced nanomaterials and the hosts' expertise in translating nanomaterials from synthesis to preclinical studies. The project targets treating non-communicable diseases, relevant to the Health pillar of the Horizon Europe programme and the emphasis on developing Advanced Materials by European Commission. It shows a great impact in helping people suffering from the high risks of already approved medication. The project will enable the Researcher to acquire professional maturity related to nanomedicine development. The dissemination of results producing multiple publications in peer-reviewed journals, talks at scientific meetings, and outreach to the general public about the development of the novel antioxidant-related stroke treatment is very probable with the completion of this project. It also creates a potential platform for the scaling process of nanomedicine through collaboration with industrial partners.

Campo scientifico (EuroSciVoc)

Questo progetto non è ancora stato classificato con EuroSciVoc.
Suggerisci i campi scientifici che ritieni più rilevanti e aiutaci a migliorare il nostro servizio di classificazione.

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-MSCA-2022-PF-01

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

UNIVERSITE PARIS CITE
Contributo netto dell'UE
€ 211 754,88
Indirizzo
85 BD SAINT GERMAIN
75006 Paris
Francia
Regione
Ile-de-France Ile-de-France Paris
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
Nessun dato